Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The company is headquartered in Worthing, West Sussex and currently employs 602 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. The company sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Follow-Up Questions
Who is the CEO of Allergy Therapeutics PLC?
Mr. Manuel Llobet is the Chief Executive Officer of Allergy Therapeutics PLC, joining the firm since 2009.
What is the price performance of AGYTF stock?
The current price of AGYTF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Allergy Therapeutics PLC?
Allergy Therapeutics PLC belongs to Pharmaceuticals industry and the sector is Health Care
What is Allergy Therapeutics PLC market cap?
Allergy Therapeutics PLC's current market cap is $0
Is Allergy Therapeutics PLC a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Allergy Therapeutics PLC, including 3 strong buy, 5 buy, 2 hold, 0 sell, and 3 strong sell
